(Total Views: 139)
Posted On: 06/05/2024 5:09:23 PM
Post# of 124
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate
Annovis Bio (NYSE: ANVS), a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”) will host an investor webcast. According to the announcement, during the webcast, Annovis Bio officials will discuss recent advancements in the development of Buntanetap, the company’s lead drug candidate, as well as strategic plans for upcoming clinical trials and an overview of the company’s progress along with its future direction. The call is slated for June 11, 2024, at 4:30 p.m. ET. Buntanetap has been formulated to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. By improving synaptic transmission and axonal transport while also reducing neuroinflammation, the drug works to reverse neurodegeneration in AD, PD and other neurodegenerative diseases.
About Annovis Bio Inc.
For more information about the company, visit www.AnnovisBio.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”) will host an investor webcast. According to the announcement, during the webcast, Annovis Bio officials will discuss recent advancements in the development of Buntanetap, the company’s lead drug candidate, as well as strategic plans for upcoming clinical trials and an overview of the company’s progress along with its future direction. The call is slated for June 11, 2024, at 4:30 p.m. ET. Buntanetap has been formulated to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. By improving synaptic transmission and axonal transport while also reducing neuroinflammation, the drug works to reverse neurodegeneration in AD, PD and other neurodegenerative diseases.
About Annovis Bio Inc.
For more information about the company, visit www.AnnovisBio.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
